The Broad will now offer licenses for both its own CRISPR IP and MilliporeSigma's to companies using CRISPR in their research and development activities.
Mirnax will use Arcis' nucleic acid sample preparation and preservation technology to improve the stability of miRNA biomarkers for early disease detection.
Oncore and its partners will commercialize GeneNews' ColonSentry test in all countries outside the US and Canada under the five-year exclusive agreement
ERS Genomics was founded to provide access to foundational CRISPR-Cas9 IP held by Emmanuelle Charpentier for applications other than human disease treatment.
Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.
The partners will offer Onegevity's GutBio assay, which integrates metagenomic sequencing with AI-based personalized recommendations to improve gut health, in Japan.
The agriculture company said it will use the technology it has licensed for new applications in crop editing and for research to bring new foods to market.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
